Showing 118 of 118on this page. Filters & sort apply to loaded results; URL updates for sharing.118 of 118 on this page
Verastem Oncology Announces FDA Acceptance and Priority Review of New ...
Verastem Oncology Receives FDA Orphan Drug Designation for Avutometinib ...
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for ...
Verastem Oncology向 FDA提交靶向药物组合 Avutometinib-Defactinib 联合用于卵巢癌治疗【精准肿瘤资讯 ...
Verastem Stock Ignites Retail Buzz After Early Cancer Drug Data Show ...
MAESTrO: Verastem Oncology granted fast track designation for ...
Verastem Oncology Reports First Quarter 2023 Financial Results and ...
Verastem Oncology Announces Initiation of a Confirmatory Phase 3 Trial ...
Verastem Oncology to Present at the Stifel 2023 Virtual Targeted ...
Verastem gets FDA approval for Avmapki + Fakzynja | PharmaShots posted ...
Verastem Gets FDA Approval for KRAS-Mutated Ovarian Cancer Drug ...
Verastem Oncology Announces Initial Results of RAMP 203 Trial of ...
Verastem Oncology Exercises Option Early to License VS-7375, an Oral ...
FLASCO / Verastem Oncology Receives FDA Approval of COPIKTRATM ...
Verastem wins first FDA approval for ovarian cancer therapy
Verastem Oncology Announces Reverse Stock Split | citybiz
Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an ...
Verastem Inc (VSTM) Profile, Company FAQs & Facts, Industry, Sector ...
Verastem Oncology announces selection of oral KRAS G12D inhibitor ...
Verastem Gets FDA Approval for Leukemia Drug, Will Make It Immediately ...
Verastem Begins U.S. Trial for KRAS G12D Inhibitor VS-7375
Verastem Unveils Promising VS-7375 Study Results: Unlocking a Potential ...
Verastem Oncology Announces First Patient Dosed with VS-7375, an Oral ...
Verastem Advances with Phase 3 Trial Progress and Product Launch ...
Verastem Oncology | Biopharmaceutical Company
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial ...
Verastem Oncology Announces Late-Breaking Abstract from Partner ...
Verastem Oncology (VSTM) - Revenue
Verastem hi-res stock photography and images - Alamy
Deck Review with Verastem Oncology | by Axial | Medium
Verastem Oncology Headquarters & Corporate Office
Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with ...
Verastem Reports the US FDA’s NDA Acceptance of Avutometinib Plus ...
Verastem Oncology宣布Avutometinib开发进展-动脉网
Verastem Oncology Announces Positive Efficacy Data for Partner GenFleet ...
About Verastem | Verastem Oncology
近9成难治性癌症患者肿瘤缩小！突破性疗法强力阻断RAS信号通路 Verastem Oncology今天公布了RAMP 201试验中A部分的更新 ...
Here's Why Verastem (VSTM) Is the Next Big Thing in Oncology • BioTech ...
New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls ...
Brazil. 20th Dec, 2022. In this photo illustration, the Verastem ...
Accelerated FDA Approval Makes Verastem Drug the First Therapy for Rare ...
Catalent and Verastem Partner on Newly Launched Cancer Treatment ...
Verastem Presents Avutometinib and Defactinib Combination Program ...
Verastem Oncology Announces First Patient Dosed in VS-7375 U.S. Phase 1 ...
Verastem Oncology Strengthens Executive Leadership Team with Key ...
Verastem Oncology | Clinical Studies | Clinical Trial Radar
FDA approves Verastem Oncology’s combination therapy for rare ovarian ...
Verastem announces Q3 2023 financial results and highlights recent ...
Verastem campaign highlights new meds for rare ovarian cancer
Verastem Oncology announces a new strategic direction to advance the ...
Verastem Oncology Announces Multiple Data Presentations at Society of ...
Verastem Oncology gets FDA fast track status for cancer drug
Verastem Oncology Announces First Patient Dosed with GFH375/VS-7375, a ...
Verastem Q4 Earnings Call Highlights
Verastem Ovarian Cancer Therapy: US FDA approves Verastem's ovarian ...
Verastem to jump 1,200% in wasting money on problem already solved
Verastem Oncology Announces Updated Data from Partner GenFleet ...
Verastem Oncologys Vanguard Leap A New Dawn for KRAS Mutant Ovarian ...
Verastem announces dosing of first patient in trial of KRAS G12D inhibitor
Verastem Oncology: 41% ORR for GFH375 at 600 mg QD | VSTM Stock News
Verastem Oncology on LinkedIn: #ovariancancer #knowovarian
FDA sets priority review date for Verastem Oncology’s new ovarian ...
In this photo illustration, the Verastem Oncology logo is displayed on ...
Verastem Research & Development | Verastem, Inc.
Verastem Wins Approval For Novel Drug Combo In Rare Ovarian Cancer
Verastem Oncology - LifeScienceHistory.com
パートナリング | イノベーション | 中外製薬株式会社
Who We Are | Verastem, Inc.
FDA Fast Track: Verastem's Novel KRAS G12D Cancer Treatment Advances ...
FLASCO / Drugs - FLASCO
Verastem, Inc. (VSTM) Latest Stock News & Headlines - Yahoo Finance
FDA Grants Accelerated Approval To Verastem's Combination Drug For ...
Verastem’s Dual FDA Approvals Signal a New Era in Targeted Cancer Therapies
Resources | Verastem, Inc.
FDA Approves Verastem’s Groundbreaking Ovarian Cancer Treatment
GFH375 (VS-7375): An oral, selective KRAS G12D (ON/OFF) inhibitor with ...
A New Era for Ovarian Cancer Treatment: Verastem’s FDA Approval Sparks ...
Verastem's Dual Therapy for Recurrent KRAS Mutant Low-Grade Serous ...
Verastem's Breakthrough FDA Approval for Rare Ovarian Cancer: A New Era ...
Verastem, Inc. (VSTM) Interactive Stock Chart - Yahoo Finance
Verastem, Inc. (VSTM) Stock Price, News, Quote & History - Yahoo Finance
Verastem, Inc. « Logos & Brands Directory
In this photo illustration, a smartphone with the logo of US oncology ...
First-Of-Its-Kind, Multi-National Patient Impact Survey Reveals Unique ...
The RAF/MEK clamp Avutometinib enhances antitumor efficacy of KRAS G12C ...
P:\Verastem Corporate Branding\Verastem Oncology Logos\Verastem-02.jpg
The RAF/MEK clamp avutometinib enhances antitumor efficacy of KRAS G12C ...
Empowered Patient Podcast: Developing Treatment for Rare Low-Grade ...
Verastem, Inc. (VSTM): VRIO Analysis – DCFmodeling.com
FDA Approves Verastem’s Ovarian Cancer Therapy for Some Adult Patients ...
FDA approves Verastem's combo for rare form of ovarian cancer
The RAF/MEK clamp avutometinib as the backbone of therapy for ...
Verastem, Inc. (VSTM) 8-K Earnings Release, Regulated Disclosure - Apr 2020
FDA’s Pending Approval of Verastem’s Novel Combination Therapy Signals ...
Home - Medicine to Market
Verastem: VS-7375 shows four of five tumor reductions, no DLTs | VSTM ...
Corporate Presentation June 2023
